Ramucirumab: Boon or bane
Ramucirumab is the recent addition to the list of monoclonal antibodies being tried in various malignancies. It has been approved in non-small cell lung cancer, gastric cancer and colorectal cancer after progression of one or more lines of therapies in the advanced setting. Though randomized trials...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2016-09-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1110036216300048 |